Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 8;14(6):e25745.
doi: 10.7759/cureus.25745. eCollection 2022 Jun.

Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies

Gautam Swaroop  1
Affiliations
Review

Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies

Gautam Swaroop. Cureus. .

Abstract

After myocardial infarction (MI), patients are at a greater risk of heart failure. Post-MI patients with left ventricular systolic dysfunction have a higher risk of mortality or morbidity. Strong and compelling data from randomized trials have demonstrated that drug therapies intended for preventing post-MI remodeling with neuro-hormonal inhibitors can considerably improve short- and long-term outcomes, including death, reinfarction, and worsening heart failure. This article aims at summarizing clinical data on established pharmacological therapies in treating post-MI patients with or without left ventricular systolic dysfunction (LVSD), and with or without signs and symptoms of heart failure.

Keywords: angiotensin receptor neprilysin inhibitors; angiotensin-converting enzyme inhibitors; heart failure; mineralocorticoid receptor antagonists; post-myocardial infarction; sodium-glucose co-transporter-2 inhibitors; soluble guanylate cyclase stimulators; β-blockers.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Treatment goals in patients with heart failure with reduced ejection fraction
See this image and copyright information in PMC

References

    1. Cardiovascular diseases in India: current epidemiology and future directions. Prabhakaran D, Jeemon P, Roy A. https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.114.008729. Circulation. 2016;133:1605–1620. - PubMed
    1. Mahmaljy H, Yelamanchili VS, Singhal M. Treasure Island (FL): StatPearls Publishing; 2022. Dilated cardiomyopathy. - PubMed
    1. Ischemic cardiomyopathy. Airhart S, Murali S. https://www.sciencedirect.com/science/article/pii/B978012809657410910X Encyclopedia of Cardiovascular Research and Medicine. 2018;145:54.
    1. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. Cardiovasc Ther. 2018;36:0. - PubMed
    1. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, Mielniczuk L. https://europepmc.org/article/MED/29348971. Am J Cardiovasc Dis. 2017;7:108–113. - PMC - PubMed

LinkOut - more resources